Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-finding study of HS-10542 in primary IgA nephropathy
CTR20260707Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10542 in IgA nephropathy (IgAN), sponsored by Hengrui Therapeutics. Started May 2026; status: active.
02
Drugs
HS-10542
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20260707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260707.